Document Detail

Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial.
MedLine Citation:
PMID:  13678916     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: We sought to assess whether pre-procedural angiographic characteristics are associated with adverse clinical outcomes after coronary stenting with glycoprotein IIb/IIIa inhibition.
BACKGROUND: Ischemic complications after balloon angioplasty are associated with pre- and post-procedural angiographic variables. However, in the current era of stenting with IIb/IIIa inhibition, it is unknown whether angiographic features assessed before intervention confer an increased risk of adverse procedural and subsequent clinical outcomes.
METHODS: In the Do Tirofiban and ReoPro Give Similar Efficacy Outcomes? Trial (TARGET), 4,809 patients undergoing planned stenting were randomized to tirofiban or abciximab. Baseline demographic, clinical, and angiographic variables were obtained. Clinical end points were recorded at 30 days and six months. The relationship between angiographic variables and adverse clinical outcomes was assessed.
RESULTS: Patients with the combination of thrombus, lesion eccentricity, and lesion length >20 mm had a 21.4% composite incidence of death, myocardial infarction, or urgent target vessel revascularization (TVR) at 30 days, compared with 4.2% in those patients without these high-risk features (hazard ratio [HR] 3.24, p < 0.001). After adjustment, the risk was independently associated with thrombus (HR 1.40, p = 0.034), eccentricity (HR 1.67, p < 0.001), and lesion length >20 mm (HR 1.89, p < 0.001). The risk of six-month TVR was independently associated with left anterior descending coronary artery lesions (HR 1.46, p < 0.001), restenotic lesions at baseline (HR 1.58, p = 0.006), and lesion length (HR 1.19, p = 0.03).
CONCLUSIONS: Patients with thrombus, eccentric lesions, or lesion length >20 mm are at high risk for ischemic outcomes after coronary stenting, despite IIb/IIIa inhibition. Further research into novel anti-thrombotic therapies or procedural strategies is necessary for these patients.
Mitchell J Ross; Howard C Herrmann; David J Moliterno; James C Blankenship; Laura Demopoulos; Peter M DiBattiste; Stephen G Ellis; Ziyad Ghazzal; Jack L Martin; Jennifer White; Eric J Topol
Related Documents :
12818236 - Angina pectoris: interventional therapies and treatment of restenosis.
15974886 - Stent-based delivered anti-proliferative drugs in the prevention of coronary stent rest...
21547406 - A study to determine chest wall vibratory attachment interface locations for a low freq...
17413036 - Low levels of nogo-b in human carotid atherosclerotic plaques are associated with an at...
21461336 - Statins: cardiovascular risk reduction in percutaneous coronary intervention-basic and ...
3864436 - The extracranial-intracranial bypass study: how will the outcome affect us?
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  42     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2003 Sep 
Date Detail:
Created Date:  2003-09-18     Completed Date:  2003-11-03     Revised Date:  2013-05-24    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  981-8     Citation Subset:  AIM; IM    
Division of Cardiology, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Balloon, Coronary / adverse effects*
Antibodies, Monoclonal / therapeutic use*
Coronary Angiography*
Double-Blind Method
Immunoglobulin Fab Fragments / therapeutic use*
Ischemia / etiology*
Middle Aged
Multivariate Analysis
Platelet Aggregation Inhibitors / therapeutic use*
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
Predictive Value of Tests
Risk Assessment
Stents / adverse effects*
Tyrosine / analogs & derivatives,  therapeutic use*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunoglobulin Fab Fragments; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 144494-65-5/tirofiban; 55520-40-6/Tyrosine; X85G7936GV/abciximab
Comment In:
J Am Coll Cardiol. 2003 Sep 17;42(6):989-90   [PMID:  13678917 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Outcomes of optimal or "stent-like"balloon angioplasty in acutemyocardial infarction: the CADILLAC t...
Next Document:  Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by ...